Peer Review History
| Original SubmissionJune 10, 2019 |
|---|
|
PONE-D-19-16445 No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in preclinical Alzheimer’s disease PLOS ONE Dear Dr Gilligan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The limited sample size could pose an issue questioning if the result is false negative (about the relationship between changes in structural connectivity and functional connectivity), as raised by the reviewer #2. The reviewer #1 also raised an important question about the network sparsity level and its potential influence to results. Please address them carefully in addition to other reviewers' comments. We would appreciate receiving your revised manuscript by Aug 22 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Han Zhang, Ph.D Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Our internal editors have looked over your manuscript and determined that it may be within the scope of our Early Diagnosis and Treatment of Alzheimer's Disease Call for Papers. This collection of papers is headed by a team of Guest Editors for PLOS ONE: Michael Weiner, Roberta Brinton, Jussi Tohka and Yona Levites. With this Collection we hope to bring together researchers working on a wide range of disciplines, from molecular and preclinical work, through to patient-centered studies, including clinical trials. Additional information can be found on our announcement page: https://collections.plos.org/s/alzheimersdisease. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. Agreeing to part of the call-for-papers will not affect the date your manuscript is published. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This paper investigated changes in functional and structural connectivity among regions that support memory function in preclinical Alzheimer’s disease. Then investigated the relationship between white matter tracts (fornix, cingulum bundles, and uncinate fasciculus) and functional connectivity. It’s very interesting and meaningful. But there are some issues to be resolved as following. Main concerns: 1. L313: “Cost (sparsity) was set at 0.15”. How about other costs? Are the results similar or seriously different? 2. L292: “Within hemisphere only analyses were conducted, across hemisphere connectivity was not inspected due to sample size”. It’s better and possible to make a comparison across hemisphere because authors didn’t use multivariate. 3. L272: “Its lmrob function fits a model based on an M-estimator using iteratively reweighted least squares estimation”. Could you list the model equation in details? Minor concerns: 1. the figures aren’t with enough resolution, especially the title and number are unclear. 2. Table 3,4, why t(43), what does 43 mean? And the table format should be revised for consistency. 3. Some expressions are unclear, e.g. L54: “……. more so than local neuropathological processes”. L91: “ and to a lesser extent in MCI, found using a graph theory approach ” Reviewer #2: The study used multimodal MRI data including DWI and resting state MRI to compared the difference between MCI and AD. This study has some strengths, such as the advanced analytical method. But there are still several important details need to be clarified. 1. The concept of preclinical stage of AD is definitely not MCI. Cited from a review (Epelbaum et al., 2017), three main issues concerning the concept of preclinical AD must be clarified: 1) the level of cognitive performance considered as normal cognition, 2) the changes in cognitive performance considered as cognitive decline, and 3) the best biomarkers or the best combination of them able to identify the “AD pathophysiological signature” in vivo. Hence, the stage of MCI should be prodromal AD, but not preclinical. Please clarify all related content. Ref: Epelbaum S, Genthon R, Cavedo E, et al. Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept [J]. Alzheimers Dement, 2017, 13(4): 454-67. 2. In the section of Introduction, I think it would have been better to propose the research aims at the last paragraph after review all the related studies and their limitation. 3. In line 142, the cut-off score in GDS is 5? 4. In Line 275-277,” We chose not to include depression as a control covariate given that its presence may reflect dementia pathology rather than a reaction to memory problems.” The relationship between depression and cognitive function is very complicated, part of the depressive elderly would never convert to dementia. This sentence is confusing. Please clarify and revise related analysis result. 5. The author should clarify the definition of DMN-a, -b and -c, because it seems very confusing for a clinician reading. 6. Due to the small sample size, I think it is better to compare with age, gender matched controls. In addition, the age distribution was “54-80”. For neuroimage study, especially AD-related study, age is a very important factor. 7. About method, there are some significant difference between group in neuropsychological test, such as MMSE, word delay test, so what’s the relationship between the neuroimage biomarker with these clinical data. Please do some further correlation analysis which may reflect the clinical implication. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Ling Yue [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
[EXSCINDED] PONE-D-19-16445R1 No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in prodromal Alzheimer’s disease PLOS ONE Dear Dr Gilligan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Specifically, please make clarification regarding reviewer #1's minor concern. It may not need a re-review. We would appreciate receiving your revised manuscript by Oct 20 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Han Zhang, Ph.D Academic Editor PLOS ONE Additional Editor Comments (if provided): Please address the reviewer #1's minor concern. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Minor concerns: The sign of static value in different tables may not be consistent. For example, in table 2, positive statistic value means increase in MCI subjects, negative means decrease. But in table 3, they show opposite meaning according to the results description. The statistic value means T value? It's better to be clearer in each table. Reviewer #2: The authors addressed all the comments adequately, and their manuscript is significantly improved. I have no further comments. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in prodromal Alzheimer’s disease PONE-D-19-16445R2 Dear Dr. Gilligan, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Han Zhang, Ph.D Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-19-16445R2 No relationship between fornix and cingulum degradation and within-network decreases in functional connectivity in prodromal Alzheimer’s disease Dear Dr. Gilligan: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Han Zhang Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .